Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus fluticasone/salmeterol in moderate-to-severe COPD
2012-005087-10Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing QVA149 arm with Fluticasone/salmeterol arm (2 arms). Primary endpoint: Standardized FEV1 AUC0-12h at 12 weeks. Started Feb 2013; status: completed.
02
Drugs
indacaterol + glycopyrroniumsalmeterol + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-005087-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005087-10.